SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $RHHBY–Wilserdly (giredestrant) is now FDA-approved for ER+, ESR1-mutated advanced breast cancer, offering a new option to help delay disease progression.

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.